Align Technology's leading Invisalign ecosystem, strong cash generation, and activist-led efficiency agenda offer substantial long-term upside despite near-term ASP, scanner-transition, and regulatory pressure.
Overview
Align Technology is a leading global medical-device company that connects Invisalign clear aligners with iTero scanners, ClinCheck treatment planning, exocad software, Vivera retainers, and automated manufacturing. The ecosystem has treated more than 23 million cases and supports an estimated 68.8%-70% global clear-aligner share, creating clinical data, brand, workflow, and switching-cost advantages. **Q2 2026 revenue reached a record $1,056.2 million, up 4.3% year over year, while non-GAAP operating margin was 22.9% and non-GAAP diluted EPS was $2.64.** Clear Aligner revenue grew 8.2% to $870.9 million, but Systems and Services fell 10.8% to $185.3 million during the transition to lower-cost leasing models. Management reiterated FY2026 revenue growth of 3%-4%, with aligner volumes up approximately 6% but flat to slightly down ASP and Systems and Services down 6%-8%; Q3 revenue guidance of $1.00 billion-$1.02 billion was below consensus. The stock traded near $159 after a 6.07% after-hours decline, but the report sees upside from Elliott's board refresh, operational review, $400 million-$500 million buybacks, and a $253.42 probability-weighted five-year target.